An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs)
Patients suffering from pancreatic neuroendocrine tumors (pNETs) are now candidates to receive novel approved drugs that have demonstrated benefit in disease control rate and delay the time taken for tumor progression in Phase III clinical trials; for example, sunitinib, everolimus and lanreotide. T...
| Main Authors: | , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Springer Healthcare
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837935/ |